CA2375033A1 - Vaccins contre des antigenes dependant de la conformation ainsi que contre des antigenes qui ne sont pas ou pas exclusivement des proteines ou des peptides - Google Patents

Vaccins contre des antigenes dependant de la conformation ainsi que contre des antigenes qui ne sont pas ou pas exclusivement des proteines ou des peptides Download PDF

Info

Publication number
CA2375033A1
CA2375033A1 CA002375033A CA2375033A CA2375033A1 CA 2375033 A1 CA2375033 A1 CA 2375033A1 CA 002375033 A CA002375033 A CA 002375033A CA 2375033 A CA2375033 A CA 2375033A CA 2375033 A1 CA2375033 A1 CA 2375033A1
Authority
CA
Canada
Prior art keywords
peptides
antigen
conformation
dna
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002375033A
Other languages
English (en)
Inventor
Steffen Goletz
Uwe Karsten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2375033A1 publication Critical patent/CA2375033A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procédé qui permet d'appliquer la technologie extrêmement performante de la vaccination à l'aide d'acide désoxyribonucléique (ADN) non seulement sur des épitopes de séquence de protéines ou de peptides, mais aussi sur des épitopes de conformation. Ce procédé permet en outre l'utilisation de la vaccination à l'ADN pour des antigènes qui ne sont pas ou pas exclusivement des protéines ou des peptides. Le vaccin préféré selon la présente invention contient en tant que constituant essentiel un acide désoxyribonucléique (ADN) codant une séquence peptidique qui représente quant à elle l'imitation immunologique (mimétisme) d'un antigène dépendant de la conformation, y compris des épitopes de conformation protéiques, ou d'un antigène qui n'est pas ou qui n'est que partiellement une protéine ou un peptide. Le peptide d'imitation qui est ou peut être également une partie du vaccin selon la présente invention est soit un anticorps antiidiotype, un fragment d'anticorps, un peptide dérivé dudit fragment ou un peptide à liaison spécifique obtenu par sélection dans une génothèque peptidique. Les domaines d'utilisation de la présente invention sont l'immunologie médicale et vétérinaire, dont la thérapie d'accompagnement pour les pathologies tumorales.
CA002375033A 1999-05-27 2000-05-29 Vaccins contre des antigenes dependant de la conformation ainsi que contre des antigenes qui ne sont pas ou pas exclusivement des proteines ou des peptides Abandoned CA2375033A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19924405.7 1999-05-27
DE19924405 1999-05-27
DE19943016 1999-09-09
DE19943016.0 1999-09-09
PCT/DE2000/001809 WO2000073430A2 (fr) 1999-05-27 2000-05-29 Vaccins contre des antigenes dependant de la conformation ainsi que contre des antigenes qui ne sont pas ou pas exclusivement des proteines ou des peptides

Publications (1)

Publication Number Publication Date
CA2375033A1 true CA2375033A1 (fr) 2000-12-07

Family

ID=26053552

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002375033A Abandoned CA2375033A1 (fr) 1999-05-27 2000-05-29 Vaccins contre des antigenes dependant de la conformation ainsi que contre des antigenes qui ne sont pas ou pas exclusivement des proteines ou des peptides

Country Status (5)

Country Link
EP (1) EP1181058A2 (fr)
AU (1) AU6424300A (fr)
CA (1) CA2375033A1 (fr)
DE (1) DE10027695A1 (fr)
WO (1) WO2000073430A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US8030025B2 (en) 2008-02-20 2011-10-04 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8642276B2 (en) * 2002-07-22 2014-02-04 Glycotope Gmbh Method for the production of an immunostimulating mucin (MUC1)
US20140206021A1 (en) * 2002-12-03 2014-07-24 North Carolina State University Prion protein ligands and methods of use

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
AU696764B2 (en) 1994-03-08 1998-09-17 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP1313512A4 (fr) 2000-08-04 2004-08-25 Human Genome Sciences Inc Facteur 2 de croissance endoth liale (vegf-2)
JP2004536579A (ja) * 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
WO2004003144A2 (fr) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Anticorps qui se lient specifiquement a reg iv
GB0324265D0 (en) * 2003-10-16 2003-11-19 Medical Res Council Peptide
EP1735347B1 (fr) * 2004-03-29 2012-11-07 The University Court of The University of Aberdeen Molecules de liaison specifiques diriges contre la synaptophysine
RU2007139283A (ru) * 2005-03-25 2009-04-27 Гликарт Биотехнологи Аг (Ch) АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, НАПРАВЛЕННЫЕ К MCSP И ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ СВЯЗЫВАНИЯ Fc-РЕЦЕПТОРА И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
ATE537188T1 (de) 2005-05-18 2011-12-15 Ablynx Nv Serumalbuminbindende proteine
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
CN1301267C (zh) * 2005-06-21 2007-02-21 中国人民解放军军事医学科学院附属医院 Muc1粘蛋白的一个模拟表位肽及其编码dna与应用
CN102037007A (zh) 2008-01-25 2011-04-27 奥尔胡斯大学 选择性外部位点抑制papp-a对igfbp-4的活性
EP3059247B1 (fr) 2008-12-05 2017-09-20 Abraxis BioScience, LLC Peptides de liaison à sparc et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04304897A (ja) * 1991-04-01 1992-10-28 Kyowa Hakko Kogyo Co Ltd 抗イディオタイプモノクローナル抗体
DE19627352A1 (de) * 1996-06-27 1998-01-02 Max Delbrueck Centrum Vakzine gegen Kohlenhydrat-Antigene
AU2657599A (en) * 1998-02-04 1999-08-23 Trustees Of The University Of Pennsylvania, The Peptide mimotopes of carbohydrate antigens
GB9808327D0 (en) * 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US8642276B2 (en) * 2002-07-22 2014-02-04 Glycotope Gmbh Method for the production of an immunostimulating mucin (MUC1)
US9487567B2 (en) 2002-07-22 2016-11-08 Glycotope Gmbh Method for the production of an immunostimulating mucin (MUC1)
US20140206021A1 (en) * 2002-12-03 2014-07-24 North Carolina State University Prion protein ligands and methods of use
US9678085B2 (en) * 2002-12-03 2017-06-13 Pathogen Removal And Diagnostic Technologies Inc. Prion protein ligands and methods of use
US8030025B2 (en) 2008-02-20 2011-10-04 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8221749B2 (en) 2008-02-20 2012-07-17 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US10336820B2 (en) 2008-02-20 2019-07-02 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

Also Published As

Publication number Publication date
EP1181058A2 (fr) 2002-02-27
WO2000073430A3 (fr) 2001-03-29
WO2000073430A2 (fr) 2000-12-07
DE10027695A1 (de) 2001-04-19
AU6424300A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
CA2375033A1 (fr) Vaccins contre des antigenes dependant de la conformation ainsi que contre des antigenes qui ne sont pas ou pas exclusivement des proteines ou des peptides
Apostolopoulos et al. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens
EP0804231B1 (fr) Peptides synthetiques a repetitions en tandem multiples, a base de mucine et d'analogues, et utilisations
US6344203B1 (en) Mimicking peptides in cancer therapy
US7854931B2 (en) Immunizing compostion and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein
CA2468259C (fr) Anticorps dirige contre des proteines membranaires latentes (lmp) et utilisations de ceux-ci
CZ294425B6 (cs) Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor
AU2006228067A1 (en) Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
Manoutcharian et al. Phage displayed biomolecules as preventive and therapeutic agents
CA2253602A1 (fr) Methode et composition permettant de modifier la configuration des antigenes a epitopes multiples pour provoquer une reponse immunitaire
US6656481B1 (en) Vaccinal preparations
RU2322260C2 (ru) Пассивная иммунизационная терапия на основе пептидов для лечения атеросклероза
MXPA01007148A (es) Uso de anticuerpos para vacunacion anti-cancer.
AU2018359358B2 (en) Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
JPWO2020206330A5 (fr)
Vichier‐Guerre et al. Short synthetic glycopeptides successfully induce antibody responses to carcinoma‐associated Tn antigen
WO2001081371A1 (fr) Peptides gd3 mimetiques
Ježek et al. Solid phase synthesis of glycopeptide dendrimers with Tn antigenic structure and their biological activities. Part I
JP2002533357A (ja) 疾病の治療に有用なペプチドミミック
JP5534630B2 (ja) Ｇｄ３模倣ペプチド
KR100372958B1 (ko) 면역반응을개시시키기위해다중에피토프항원의입체형태를변화시키기위한방법및조성물
AU711270C (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
JP2000511764A (ja) マウスモノクローナル抗イディオタイプ抗体１１ｄ１０およびその使用方法
Cramer Book Review: The Importance of Antibody Pathways for the Rejection of Xenografts: An Immunological Conundrum?
Apostolopoulos et al. Murine Immune Response to Cells Transfected with Human MUC1: Immunization

Legal Events

Date Code Title Description
FZDE Dead